Takeda Chemical Industries, Inc.

Hisamitsu Pharmaceutical Company, Inc.

Teikoku Hormone Mfg. Co., Ltd.

Advance Co., Ltd.

Shigeo Yanai

Katsumi Iga

Yukihiro Matsumoto

Naruhito Higo

Hiroaki Okada

Yohko Akiyama

Naoki Nagahara

Kazuhiro Saito

Keiichiro Okabe

Katsuichi Sudo

Masaki Itoh

A hydrophilic membrane having a low adsorptivity for a protein is disposed, as an interface, on a side to be contacted with a skin, and a drug such as a physiologically active peptide is transdermally delivered by iontophoresis. The membrane has an adsorptivity for a protein of not greater than 10 &mgr;g/cm . The thickness of the membrane is about 10 to 200 &mgr;m, and the porosity of the membrane is about 60 to 90%. Such membrane includes a hydrophilized fluororesin membrane, a hydrophilized polysulfone membrane and a hydrophilized cellulose derivative membrane.

Interface for iontophoresis

A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density. The method insures excellent pharmacologic efficacy with a low risk for side effects in the prevention and therapy of (1) angina pectoris, (2) unstable angina and (3) ischemic complications and coronary arterial reocclusion or restenosis associated with PTCA or coronary thrombolysis.

Method for transdermal administration of GP IIb/IIIa antagonist

The present invention relates to a pharmaceutical composition for oral administration in which a fumagillol derivative is stabilized and exhibits remarkable antiangiogenesis activity in oral administration.

Oral composition of fumagillol derivative

A calcitonin, its derivative or a salt thereof is transdermally delivered by iontophoresis in which a substantially constant voltage in the range of 3 to 20 V is applied at an electric current of 0.05 to 0.5 mA/cm.sup.2. In this process, the calcitonin can be delivered transdermally with a higher absorptivity by applying a higher voltage for a short period (at a voltage of about 6 to 14 V for about 5 to 15 minutes) in the initial stage of the voltage application, and then applying a lower voltage for a long period (at a voltage of about 3 to 9 V for about 30 to 40 minutes).

Transdermal drug delivery process

A pharmaceutical composition having improved stability which comprises a fumagillol derivative and a fatty acid ester of glycerin or polyglycerin is disclosed. The composition is useful for treating diseases associated with angiogenesis such as hepatoma, etc.

Stable pharmaceutical composition of fumagillol derivatives

Growing community of inventors

Himeji, Japan

Shigeo Yanai